The Many Aspects of Off-Label Prescribing in Oncology

• Anna Gu

  Department of Pharmacy Administration, St. John’s University, USA

• Albert I. Wertheimer

  Department of Pharmacy Practice, Temple University, USA

 Off-label prescribing is particularly common in oncology. While it brings abundant benefits to cancer treatment, decisions on off-label prescribing should be made with caution, due to insufficient supporting data, weak safety monitoring system, and increased health care burden. Currently, reimbursement decisions for off-label oncology are based on recommendations from four drug compendia, each of which combines data from clinical trials and/or observational studies and expert opinions. Further enhancements are expected in terms of transparency and consistency of compendia's methods of data synthesis. While the existing FDA regulations prohibit direct-to-prescriber promotion, with the exception of publication on off-label drug use, considerable leeway may be given to late-stage cancer patients. Clinical Trials for oncology off-label indication should focus on late stage cancer patients beyond first-line therapy and patient sample should have equal representations from academic and community settings. Off-label oncology clinical trials should also provide full information on conflict of interest. Given the high stakes involved in oncology treatment, future policies should strike a balance between innovation and clinical, economic, and humanistic consequences.

Laetz T, Silberman G. Reimbursement policies constrain the practice of oncology. JAMA 1991; 266: 2996-9. http://dx.doi.org/10.1001/jama.1991.03470210064033

Soares M. “Off-label” indications for oncology drug use and drug compendia: History and current status. J Oncol Pract 2005; 1: 102-5. http://dx.doi.org/10.1200/JOP.1.3.102

Stephen R, Knopf K, Reynolds MW, Luo W, Fraeman K. Off-label use of oncology drugs in a community oncology EMR database. Poster presentation presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual meeting. May 2009, Orlando FL.

MD Anderson Cancer Center. How Common Is Use of Off-Label Drugs in Breast Cancer? July 2009. Accessed February 5, 2013. Available from: http: //www.mdanderson. org/newsroom/cancer-newsline/cancer-newsline-topics/2009/ how-common-is-use-of-off-label-drugs-in-breast-cancer-.html

Tabarrok A. From off-label prescribing towards a new FDA. Med Hypotheses 2009; 72: 11-3. http://dx.doi.org/10.1016/j.mehy.2008.08.009

American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J Clin Oncol 2006; 24: 3206-8. http://dx.doi.org/10.1200/JCO.2006.06.8940

Casali PG, Executive Committee of ESMO. The off-label use of drugs in oncology: A position paper by the European Society of Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923-5. http://dx.doi.org/10.1093/annonc/mdm517

Conroy S, Newman C, Gudka. Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children. Ann Oncol 2003; 14: 42-7. http://dx.doi.org/10.1093/annonc/mdg031

Epstein RS, Huang SM. They many sides of off-label prescribing. Clin Pharmacol Therap 2012; 91(5): 755-8. http://dx.doi.org/10.1038/clpt.2012.37

Stafford RS. Regulating off-label drug use – rethinking the role of the FDA. N Engl J Med 2008; 358; 14; 1427-9. http://dx.doi.org/10.1056/NEJMp0802107

Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 2008; 26(36): 5994-6000. http://dx.doi.org/10.1200/JCO.2008.18.1420

Batchelor TT, Kolak G, Ciordia R, Ciordia R, Foster CS, Henson JW. High-Dose Methotrexate for Intraocular Lymphoma. Clin Cancer Res 2003; 9: 711-5.

Thiel EK, Wagner JT, Bechrakis NE, Coupland SE, Schmittel A, Fischer L, et al. Ifosfamide for intraocular lymphoma. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; Vol 22, No 14S (July 15 Supplement), 1520.

Abelson R, Pollack A: Medicare widens drugs it accepts for cancer. New York Times, January 27, 2009. Available from: http: //www.nytimes.com/2009/01/27/health/27cancer.html? pagewanted=all&_r=0 Accessed on March 1st, 2013.

Eastman P. Reimbursement Policies Discourage Off-Label Drug Use. Oncol Times 2005; 27(20): 8-10. http://dx.doi.org/10.1097/01.COT.0000290944.45158.35

Pan DJD. Monitoring the Safety of Medicines Used Off-Label. Clin Pharmacol Therap 2012; 91(5): 787-95. http://dx.doi.org/10.1038/clpt.2012.24

Gillick MR. Controlling off-label medication use. Ann Intern Med 2009; 150: 344-7. http://dx.doi.org/10.7326/0003-4819-150-5-200903030-00108

Kesselheim AS, Mello MM, Avorn J. FDA regulation of Off-label drug promotion under attack. JAMA 2013; 309(5): 445-6. http://dx.doi.org/10.1001/jama.2012.207972

Aronson FR, Ernest ML, Tasch M, Cusack DM. Insurance coverage for investigational therapy (letter). J Natl Cancer Inst 1990; 82: 1434. http://dx.doi.org/10.1093/jnci/82.17.1434

Pfister DG. Off-label use of oncology drugs: The need for more data and then some. J Clin Oncol 2012; 30: 584-6. http://dx.doi.org/10.1200/JCO.2011.38.5567

Tillman K, Burton B, Jacques LB, Phurrough SE. Compendia and anticancer therapy under Medicare. Ann Intern Med 2009; 150(5): 348-50. http://dx.doi.org/10.7326/0003-4819-150-5-200903030-00109

Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, et al. Systematic review: reliability of compendia methods for off-label oncology indication. Ann Intern Med 2009; 150: 336-43. http://dx.doi.org/10.7326/0003-4819-150-5-200903030-00107

National Comprehensive Cancer Network (NCCN). The NCCN Drugs and Biologics Compendium. NCCN Compendium™. Accessed April 18, 2013. Available from http://www.nccn.org/professionals/drug_compendium/content/contents.asp

Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among off-based physicians. Arch Intern Med 2006; 166: 1021-6. http://dx.doi.org/10.1001/archinte.166.9.1021

Teagarden JR, Dreitlein WB, Kourlas H, Nichols L. Influence of pharmacy benefit practices on off-label dispending of drugs in the United States. Clin Pharmacol Therap 2012; 91(5): 943-5. http://dx.doi.org/10.1038/clpt.2011.367

American Association for Cancer Research. FDA issues new off-label guidelines. Available from: http://www.aacr.org/ home/public--media/science-policy--government-affairs/aacr-cancer-policy-monitor/aacr-cancer-policy-monitor-february/ fda-issues-new-off-label-guidelines.aspx assessed on February 20, 2013.

FDA: Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices. Available from: www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf Accessed February 13, 2013.

Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S. Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. J Clin Oncol 2012; 30(6): 661-6. http://dx.doi.org/10.1200/JCO.2011.35.5198

Irwin B, Hirsh BR, Samsa GP, Abernethy AP. Conflict of interest disclosure in off-label oncology clinical trials. J Oncol Pract 2012; 8(5): 298-302. http://dx.doi.org/10.1200/JOP.2011.000523

Bekelman JE, Li Yi, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2003; 289: 454-65. http://dx.doi.org/10.1001/jama.289.4.454

Kesselheim AS, Wang B, Studdert DM, Avorn J. Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures. PLoS Med 2012; 9(8): e1001280. http://dx.doi.org/10.1371/journal.pmed.1001280

FDA. Draft Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators; Available from: https://www.federalregister.gov/articles/ 2011/05/24/2011-12623/draft-guidance-for-clinical-investigators-industry-and-fda-staff-financial-disclosure-by-clinical assessed February 12, 2013.

Mansell P. FDA guidance on investigator financial disclosures needs more work, says WLF. Available from: http://www.pharmatimes.com/article/11-08-04/FDA_guidance _on_investigator_financial_disclosures_needs_more_work_says_WLF.aspx. Accessed February 12, 2013.

• PDF